E-LIB Suche - Ergebnisse für: van Waarde, Aren

1

Pharmacokinetic Analysis of [18F]FES PET in the Human Brain..:

Ghazanfari, Nafiseh ; Doorduin, Janine ; van der Weijden, Chris W. J....
Molecular Imaging and Biology. 26 (2024) 2 - p. 351-359 , 2024

Link: https://doi.org/10.1007/..

2

Effects of the adenosine A2A receptor antagonist KW6002 on ..:

Prasad, Kavya ; de Vries, Erik F.J. ; van der Meiden, Esther...
Neuropharmacology. 247 (2024) - p. 109862 , 2024

Link: https://doi.org/10.1016/..

3

Characterization of a novel model for atherosclerosis imagi..:

Sijbesma, Jürgen W. A. ; van Waarde, Aren ; Kristensen, Sebastiaan...
EJNMMI Research. 13 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

4

Perinatal exposure to the immune-suppressant di-n-octyltin ..:

de Groot, Didima M. G. ; Linders, Louisa ; Kayser, Reinier...
Toxicology Mechanisms and Methods. 34 (2023) 3 - p. 283-299 , 2023

Link: https://doi.org/10.1080/..

5

Characterization of a novel model for atherosclerosis imagi..:

Sijbesma, Jürgen W.A ; van Waarde, Aren ; Kristensen, Sebastiaan...
https://research.rug.nl/en/publications/1679ca03-2fde-43bf-a560-0eab1b6ce1ca. , 2023

Link: https://hdl.handle.net/1..

6

Perinatal exposure to the immune-suppressant di-n-octyltin ..:

Didima M. G. de Groot ; Louisa Linders ; Reinier Kayser...
doi:10.6084/m9.figshare.24591052.v1. , 2023

Link: https://doi.org/10.6084/..

7

Characterization of a novel model for atherosclerosis imagi..:

Sijbesma, Jürgen W. A ; van Waarde, Aren ; Kristensen, Sebastiaan...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10713960/. , 2023

Link: http://www.ncbi.nlm.nih...

8

Characterization of a novel model for atherosclerosis imagi..:

Jürgen W. A. Sijbesma ; Aren van Waarde ; Sebastiaan Kristensen...
https://doi.org/10.1186/s13550-023-01055-5. , 2023

Link: https://doi.org/10.1186/..

9

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 t..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
Molecular Pharmaceutics. 19 (2022) 7 - p. 2287-2298 , 2022

Link: https://doi.org/10.1021/..

10

Impact of an Adenosine A2A Receptor Agonist and Antagonist ..:

Prasad, Kavya ; de Vries, Erik F. J. ; Sijbesma, Jürgen W. A....
Molecular Pharmaceutics. 19 (2022) 8 - p. 2992-3001 , 2022

Link: https://doi.org/10.1021/..

11

Pharmacokinetic Modeling of [11C]GSK-189254, PET Tracer Tar..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
Molecular Pharmaceutics. 19 (2022) 3 - p. 918-928 , 2022

Link: https://doi.org/10.1021/..

12

Dose-response assessment of cerebral P-glycoprotein inhibit..:

Garcia-Varela, Lara ; Mossel, Pascalle ; Aguiar, Pablo...
Journal of Controlled Release. 347 (2022) - p. 500-507 , 2022

Link: https://doi.org/10.1016/..

13

Dose-response assessment of cerebral P-glycoprotein inhibit..:

Garcia Varela, Lara ; Mossel, Pascalle ; Aguiar, Pablo...
https://research.rug.nl/en/publications/fd0171d8-0428-4ea1-abe0-b109a1b64289. , 2022

Link: https://hdl.handle.net/1..

14

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 t..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257755/. , 2022

Link: http://www.ncbi.nlm.nih...

15

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 t..:

Ghazanfari, Nafiseh ; van Waarde, Aren ; Doorduin, Janine...
https://research.rug.nl/en/publications/b086a6af-eedc-4eb6-b817-0244a9d9697d. , 2022

Link: https://hdl.handle.net/1..